Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONTRAFECT CorpCFRX · Entity 116797 | Director | May 17, 2022 | May 18, 2022 |
| Lucid Diagnostics Inc.LUCD · Entity 6375 | Director · Chief Executive Officer | February 20, 2026 | February 25, 2026 |
| PAVmed Inc.PAVM · Entity 7317 | Director · Chairman and CEO | April 02, 2026 | April 03, 2026 |
| Viveon Health Acquisition Corp.VHAQ · Entity 138648 | Director | December 23, 2020 | December 29, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONTRAFECT Corp
Report date May 17, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2032-05-17 | Direct | 42,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 42,000 · Balance 42,000 F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date.
Lucid Diagnostics Inc.
Report date February 20, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,636,627 |
Reported balance
After 2026-02-20 transaction · row 1
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 2,170,000 · Balance 3,636,627 F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
PAVmed Inc.
Report date April 02, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 357,614 |
Reported balance
After 2026-04-02 transaction · row 1
1 source rowRow 1 · 2026-04-02 · Grant · Acquired 350,000 · Balance 357,614 F1: Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. |
| Common StockSEC Table I · non-derivative | IndirectBy daughter | 5 |
Reported balance
Holding disclosure · report date 2026-04-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5 |
| Common StockSEC Table I · non-derivative | IndirectBy son | 5 |
Reported balance
Holding disclosure · report date 2026-04-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5 |
| Common StockSEC Table I · non-derivative | IndirectBy Pavilion Venture Partners LLC | 9,904 |
Reported balance
Holding disclosure · report date 2026-04-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 9,904 F2: Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and therefore has sole voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy HCFP/AG LLC | 45 |
Reported balance
Holding disclosure · report date 2026-04-02 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 45 F3: Dr. Aklog is a co-manager of HCFP/AG LLC, and therefore has joint voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
F2: Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and therefore has sole voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein.
F3: Dr. Aklog is a co-manager of HCFP/AG LLC, and therefore has joint voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein.
Viveon Health Acquisition Corp.
Report date December 23, 2020 · Filed December 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 27,000 |
Reported balance
After 2020-12-23 transaction · row 1
1 source rowRow 1 · 2020-12-23 · Other · Acquired 27,000 · Balance 27,000 F1: Represents founders shares transferred to Mr. Aklog from Viveon Health LLC, the sponsor of the Issuer, for Mr. Aklog's service as an independent director of the Issuer. There was no consideration paid in the transfer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents founders shares transferred to Mr. Aklog from Viveon Health LLC, the sponsor of the Issuer, for Mr. Aklog's service as an independent director of the Issuer. There was no consideration paid in the transfer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2017 Filed Sep 14, 2017 17:39 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 200 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001094891-17-000236 · edgar.xml · derivative · entry 11 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,300 Underlying: Common Stock · 200 shares Expires 2022-01-29 F3 · price: The warrants were purchased at a weighted average price of approximately $2.71 per warrant. These warrants were purchased in multiple transactions at prices ranging from $2.10 to $3.32, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 17:39 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 100 | $6.66 | $666.00 |
DisclosureSEC source: 0001094891-17-000236 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,838 Read SEC document |
| September 11, 2017 Filed Sep 14, 2017 17:39 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000236 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,738 F1 · price: The shares were purchased at a weighted average price of approximately $6.383 per share. These shares were purchased in multiple transactions at prices ranging from $6.35 to $6.45, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 11:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 300 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001094891-17-000234 · edgar.xml · derivative · entry 11 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,100 Underlying: Common Stock · 300 shares Expires 2022-01-29 F3 · price: The warrants were purchased at a weighted average price of approximately $1.3167per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.15 to $1.45, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 11:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000234 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,438 F2 · price: The shares were purchased at a weighted average price of approximately $5.98 per share. These shares were purchased in multiple transactions at prices ranging from $5.73 to $6.25, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 11:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 200 | $1.20 Strike: $5.00 | $240.00 |
DisclosureSEC source: 0001094891-17-000234 · edgar.xml · derivative · entry 10 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,800 Underlying: Common Stock · 200 shares Expires 2022-01-29 Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 11:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000234 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,038 F1 · price: The shares were purchased at a weighted average price of approximately $5.11297047 per share. These shares were purchased in multiple transactions at prices ranging from $4.74 to $5.95, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| September 06, 2017 Filed Sep 7, 2017 17:46 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 800 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001094891-17-000229 · edgar.xml · derivative · entry 12 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,600 Underlying: Common Stock · 800 shares Expires 2022-01-29 F3 · price: The warrants were purchased at a weighted average price of approximately $1.20625 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.15 to $1.35, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| September 06, 2017 Filed Sep 7, 2017 17:46 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 899 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000229 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,188 F2 · price: The shares were purchased at a weighted average price of approximately $4.8544493882 per share. These shares were purchased in multiple transactions at prices ranging from $4.75 to $4.99, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 17:46 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 100 | $1.00 Strike: $5.00 | $100.00 |
DisclosureSEC source: 0001094891-17-000229 · edgar.xml · derivative · entry 11 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock · 100 shares Expires 2022-01-29 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 17:46 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 100 | $0.98 Strike: $5.00 | $98.00 |
DisclosureSEC source: 0001094891-17-000229 · edgar.xml · derivative · entry 10 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,700 Underlying: Common Stock · 100 shares Expires 2022-01-29 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 17:46 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000229 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,289 F1 · price: The shares were purchased at a weighted average price of approximately $4.73875 per share. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.99, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 11:53 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 200 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001094891-17-000227 · edgar.xml · derivative · entry 15 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,600 Underlying: Common Stock · 200 shares Expires 2022-01-29 F7 · price: The warrants were purchased at a weighted average price of approximately $1.19 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.18 to $1.20, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 11:53 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000227 · edgar.xml · nonDerivative · entry 4 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,489 F4 · price: The shares were purchased at a weighted average price of approximately $4.45666667 per share. These shares were purchased in multiple transactions at prices ranging from $4.39 to $4.50, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 11:53 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 1,700 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001094891-17-000227 · edgar.xml · derivative · entry 14 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,400 Underlying: Common Stock · 1,700 shares Expires 2022-01-29 F6 · price: The warrants were purchased at a weighted average price of approximately $1.0375 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.01 to $1.09, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 11:53 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 1,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000227 · edgar.xml · nonDerivative · entry 3 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,189 F3 · price: The shares were purchased at a weighted average price of approximately $4.2725 per share. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.40, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 30, 2017 Filed Sep 5, 2017 11:53 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 200 | $1.22 Strike: $5.00 | $244.00 |
DisclosureSEC source: 0001094891-17-000227 · edgar.xml · derivative · entry 13 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,700 Underlying: Common Stock · 200 shares Expires 2022-01-29 Read SEC document |
| August 30, 2017 Filed Sep 5, 2017 11:53 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000227 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,589 F2 · price: The shares were purchased at a weighted average price of approximately $4.19666667 per share. These shares were purchased in multiple transactions at prices ranging from $4.19 to $4.20, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 29, 2017 Filed Sep 5, 2017 11:53 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 1,200 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001094891-17-000227 · edgar.xml · derivative · entry 12 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 1,200 shares Expires 2022-01-29 F5 · price: The warrants were purchased at a weighted average price of approximately $1.4875 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.18 to $2.24, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 29, 2017 Filed Sep 5, 2017 11:53 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 1,412 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000227 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,289 F1 · price: The shares were purchased at a weighted average price of approximately $4.19770538 per share. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.20, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 22:34 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 600 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001094891-17-000225 · edgar.xml · derivative · entry 9 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,300 Underlying: Common Stock · 600 shares Expires 2022-01-29 F2 · price: The warrants were purchased at a weighted average price of approximately $1.2467 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.23 to $1.25, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 22:34 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000225 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,877 F1 · price: The shares were purchased at a weighted average price of approximately $4.21416667 per share. These shares were purchased in multiple transactions at prices ranging from $4.14 to $4.50, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:59 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 1,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000221 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,977 F2 · price: The shares were purchased at a weighted average price of approximately $4.23 per share. These shares were purchased in multiple transactions at prices ranging from $4.00 to $4.20, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 18:59 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 7,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000221 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,777 F1 · price: The shares were purchased at a weighted average price of approximately $4.21 per share. These shares were purchased in multiple transactions at prices ranging from $3.75 to $4.25, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 22, 2017 Filed Aug 25, 2017 18:56 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000219 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,877 F2 · price: The shares were purchased at a weighted average price of approximately $4.18 per share. These shares were purchased in multiple transactions at prices ranging from $4.00 to $4.25, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 21, 2017 Filed Aug 25, 2017 18:56 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000219 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,377 F1 · price: The shares were purchased at a weighted average price of approximately $4.20 per share. These shares were purchased in multiple transactions at prices ranging from $4.00 to $4.25, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 18, 2017 Filed Aug 21, 2017 11:19 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 100 | $1.50 Strike: $5.00 | $149.99 |
DisclosureSEC source: 0001094891-17-000209 · edgar.xml · derivative · entry 11 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,700 Underlying: Common Stock · 100 shares Expires 2022-01-29 Read SEC document |
| August 18, 2017 Filed Aug 21, 2017 11:19 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 100 | $1.42 Strike: $5.00 | $142.10 |
DisclosureSEC source: 0001094891-17-000209 · edgar.xml · derivative · entry 10 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,600 Underlying: Common Stock · 100 shares Expires 2022-01-29 Read SEC document |
| August 18, 2017 Filed Aug 21, 2017 11:19 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 8,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000209 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,877 F2 · price: The shares were purchased at a weighted average price of approximately $3.81 per share. These shares were purchased in multiple transactions at prices ranging from $3.573 to $4.00, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 11:19 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 1,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-17-000209 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31.477 F1 · price: The shares were purchased at a weighted average price of approximately $3.43 per share. These shares were purchased in multiple transactions at prices ranging from $3,28 to $3.50, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 18:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 100 | $3.35 | $335.00 |
DisclosureSEC source: 0001094891-17-000205 · edgar.xml · nonDerivative · entry 8 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 300 Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 18:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 100 | $3.30 | $330.00 |
DisclosureSEC source: 0001094891-17-000205 · edgar.xml · nonDerivative · entry 7 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 200 Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 18:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 100 | $3.20 | $320.00 |
DisclosureSEC source: 0001094891-17-000205 · edgar.xml · nonDerivative · entry 6 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 100 Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 18:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 285 | $3.30 | $940.50 |
DisclosureSEC source: 0001094891-17-000205 · edgar.xml · nonDerivative · entry 5 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 285 Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 18:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 300 | $3.32 | $996.00 |
DisclosureSEC source: 0001094891-17-000205 · edgar.xml · nonDerivative · entry 4 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,677 Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 18:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 400 | $3.29 | $1,315.60 |
DisclosureSEC source: 0001094891-17-000205 · edgar.xml · nonDerivative · entry 3 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,377 Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 18:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 100 | $3.24 | $324.00 |
DisclosureSEC source: 0001094891-17-000205 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,977 Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 18:21 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 500 | $3.20 | $1,600.00 |
DisclosureSEC source: 0001094891-17-000205 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,877 Read SEC document |
| January 11, 2017 Filed Jan 12, 2017 16:10 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 25,000 | $4.00 Strike: $5.00 | $100,000.00 |
DisclosureSEC source: 0001094891-17-000036 · edgar.xml · derivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 25,000 shares Expires 2022-01-29 Read SEC document |
| November 29, 2016 Filed Dec 2, 2016 18:06 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 1,777 | $9.02 | $16,035.65 |
DisclosureSEC source: 0001094891-16-000653 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,377 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.50 to $10.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote. Read SEC document |
| November 28, 2016 Filed Dec 2, 2016 18:06 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 1,000 | $9.53 | $9,530.00 |
DisclosureSEC source: 0001094891-16-000653 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,600 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.50 to $9.80, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote. Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 20:40 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 300 | $8.00 Strike: $5.00 | $2,400.00 |
DisclosureSEC source: 0001094891-16-000651 · edgar.xml · derivative · entry 7 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,550 Underlying: Common Stock · 300 shares Expires 2022-01-29 Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 20:40 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 2,200 | $8.98 | $19,766.78 |
DisclosureSEC source: 0001094891-16-000651 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,600 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.71 to $9.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 21:07 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 900 | $9.93 | $8,938.98 |
DisclosureSEC source: 0001094891-16-000646 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,400 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $10.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth this footnote. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 21:07 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 1,400 | $10.07 | $14,096.74 |
DisclosureSEC source: 0001094891-16-000646 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.995 to $10.861, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth this footnote. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 23:12 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 200 | $14.00 | $2,799.60 |
DisclosureSEC source: 0001094891-16-000612 · edgar.xml · nonDerivative · entry 6 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,100 Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 23:12 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 200 | $13.74 | $2,747.00 |
DisclosureSEC source: 0001094891-16-000612 · edgar.xml · nonDerivative · entry 5 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,900 Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 23:12 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 200 | $13.98 | $2,795.96 |
DisclosureSEC source: 0001094891-16-000612 · edgar.xml · nonDerivative · entry 4 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,700 Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 23:12 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 200 | $14.22 | $2,844.90 |
DisclosureSEC source: 0001094891-16-000612 · edgar.xml · nonDerivative · entry 3 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 23:12 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 200 | $14.46 | $2,891.30 |
DisclosureSEC source: 0001094891-16-000612 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,300 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.